Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
2021 Penn Medicine Update on FLT3i in R/R AML: Gilteritinib Mono and in Combination With Venetoclax, Newer Agents in Frontline Intensive Therapy and Post-transplant Maintenance
Comments 0
Login to view comments.
Click here to Login